Canada Surgical Site Infection Control Market Forecast 2024-2032

Canada Surgical Site Infection Control Market Forecast 2024-2032

The Canada surgical site infection control market is predicted to grow with a CAGR of 3.57% during the projection period of 2024-2032. The market was valued at $160.90 million in 2023 and is expected to reach $224.01 million by 2032. The Canada surgical site infection control market is driven by the increasing prevalence of surgical site infections (SSIs) and the resulting emphasis on patient safety and infection prevention.

MARKET INSIGHTS

Key factors include advancements in aseptic techniques, government initiatives, and the implementation of standardized SSI surveillance systems to monitor and reduce infection rates. Additionally, the rising number of surgeries, particularly among the aging population, and the focus on improving healthcare outcomes are boosting the demand for SSI control products and solutions in Canada.

The Canadian healthcare system continues to face significant challenges associated with surgical site infections (SSIs). In fact, according to the Canadian Patient Safety Institute (CPSI), SSIs are the most common type of healthcare-associated infection among surgical patients, with infections linked to 77% of patient deaths in this group. Despite advancements in aseptic techniques, antibiotic prophylaxis, and minimally invasive surgical procedures, healthcare-associated infections (HAIs) remain a persistent issue, complicating the recovery of many surgical patients.

The Centers for Disease Control (CDC) highlights that while there have been improvements in infection control practices, including enhanced operating room ventilation and sterilization methods, SSIs still contribute substantially to morbidity, prolonged hospital stays, and mortality in Canada. In response to these challenges, the ‘Safer Healthcare Now!’ initiative introduced the SSI Getting Started Kit in 2005, aimed at promoting standardized SSI prevention processes across healthcare facilities.

Since its introduction, 145 healthcare organizations throughout Canada have self-reported data on SSI prevention measures. This initiative has played a key role in improving surgical care safety, leading to a notable decline in SSI rates for clean and clean-contaminated surgeries from 2005 to 2021. These ongoing prevention efforts are a major driver of the SSI control market in Canada, as healthcare providers continue to prioritize infection prevention and patient safety to achieve better surgical outcomes.

SEGMENTATION ANALYSIS

The Canada surgical site infection control market segmentation includes procedure, type of infection, end-user, and product. The end-user segment is further classified into hospitals and ambulatory surgical centers. Surgical site infections (SSIs) account for approximately 15% of all hospital-acquired infections and are the most prevalent type of nosocomial infection among surgical patients. These infections significantly impact patient outcomes, leading to extended postoperative hospital stays, increased healthcare costs, higher rates of hospital readmission, and compromised health outcomes.

Hospitals play a crucial role as a key end-user segment in the surgical site infection control market, given their responsibility for patient care and infection prevention. As primary centers for surgical procedures, hospitals are heavily invested in implementing comprehensive infection control measures, including the adoption of advanced antiseptics, wound care products, and infection monitoring systems. The increasing focus on patient safety, adherence to stringent healthcare regulations, and the rising number of surgeries performed are driving hospitals to prioritize effective SSI prevention strategies, thereby fueling the demand for SSI control products and solutions in this segment.

COMPETITIVE INSIGHTS

Some of the prominent companies operating in the Canada surgical site infection control market are 3M Company, Ansell Ltd, Becton, Dickinson and Company (BD), etc.

Ansell is a leading global provider of protection solutions, specializing in the design, development, and manufacturing of a wide range of products, including surgical and examination gloves, industrial and household gloves, protective clothing, and condoms. The company operates through four key business segments: industrial, medical, single-use, and sexual wellness.

With a primary focus on safety, Ansell aims to deliver advanced solutions and technologies to address the challenges faced by industrial workers and healthcare professionals, ensuring their safety and protection in both professional and personal settings. Ansell has established a strong global presence, with offices and manufacturing facilities in 52 countries worldwide. The company provides protection solutions to both industrial and healthcare sectors, emphasizing innovation and value-added services to enhance its offerings.

Please Note: Report comes with PDF and Excel.